<DOC>
	<DOCNO>NCT02259088</DOCNO>
	<brief_summary>Study efficacy safety 0.5 mg ranibizumab Chinese patient diabetic macular edema ( DME )</brief_summary>
	<brief_title>A 12-month , Randomized , Efficacy Safety Study 0.5 mg Ranibizumab v Laser Chinese DME Patients</brief_title>
	<detailed_description>Study provide efficacy safety data 0.5 mg ranibizumab intravitreal injection compare laser photocaagulation Chinese patient visual impairment due DME . Treatment driven achieve vision stabilization</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female Chinese patient ≥ 18 year age diabetes mellitus HbA1c ≤10.0 % Stable medication diabetes within 3 month prior Visit 1 Visual impairment due DME BCVA score 78 39 Stroke myocardial infarction le 3 month prior screen visit Uncontrolled hypertension Active ocular infection intraocular inflammation eye Treatment antiangiogenic drug within 3 month prior baseline visit eye Active proliferative diabetic retinopathy study eye Use investigational drug within 30 day systemic antiVEGF drug within 6 month prior baseline visit Prior laser photocoagulation intraocular procedure within 3 month prior baseline study eye History intravitreal corticosteroid treatment phakic study eye , aphakic pseudophakic within 3 month prior screen Other protocol define inclusion /exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DME , macular edema , vision impairment , Chinese , diabetes</keyword>
</DOC>